![](https://endpts.com/wp-content/uploads/2021/10/Raymond-Stevens-ShouTi-Pharma-CEO-scaled.jpg)
Raymond Stevens, Structure Therapeutics CEO
Structure's oral GLP-1 produces comparable weight loss to Lilly's oral candidate
Structure Therapeutics’ oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety, sending its stock …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.